↓ Skip to main content

Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials

Overview of attention for article published in Frontiers in immunology, April 2024
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
reddit
1 Redditor

Readers on

mendeley
7 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials
Published in
Frontiers in immunology, April 2024
DOI 10.3389/fimmu.2024.1359302
Pubmed ID
Authors

Wenjing Zhang, Zhanpeng Liang, Yurong Zhao, Yanwei Li, Ting Chen, Wenxia Li, Yunqi Chen, Peiye Wu, Huatang Zhang, Cantu Fang, Luzhen Li

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 7 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 7 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 7 100%
Readers by discipline Count As %
Unspecified 7 100%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 April 2024.
All research outputs
#21,074,934
of 25,885,333 outputs
Outputs from Frontiers in immunology
#25,316
of 32,532 outputs
Outputs of similar age
#191,259
of 284,234 outputs
Outputs of similar age from Frontiers in immunology
#495
of 1,041 outputs
Altmetric has tracked 25,885,333 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 32,532 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 13th percentile – i.e., 13% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 284,234 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 19th percentile – i.e., 19% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,041 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.